ErbB-2 receptor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett mNo edit summary |
imported>Robert Badgett No edit summary |
||
Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[biochemistry]], '''erbB-2''' ('''Human Epidermal growth factor Receptor 2''', '''HER2''', '''HER-2''', '''HER2/neu''') is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | In [[biochemistry]], '''erbB-2''' ('''Human Epidermal growth factor Receptor 2''', '''HER2''', '''HER-2''', '''HER2/neu''') is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | ||
[[Trastuzumab]] is a [[monoclonal antibody]] against the ErbB-2 receptor that lengthens remission time in metastatic [[breast cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzumab--mechanism of action and use in clinical practice. | journal=N Engl J Med | year= 2007 | volume= 357 | issue= 1 | pages= 39-51 | pmid=17611206 | |||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=17611206 | doi=10.1056/NEJMra043186 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 11:31, 23 March 2010
- The content on this page originated on Wikipedia and is yet to be significantly improved. Contributors are invited to replace and add material to make this an original article.
In biochemistry, erbB-2 (Human Epidermal growth factor Receptor 2, HER2, HER-2, HER2/neu) is a cell surface receptor that is a "protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (epidermal growth factor receptor), the erbB-3 receptor and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members."[1]
Trastuzumab is a monoclonal antibody against the ErbB-2 receptor that lengthens remission time in metastatic breast cancer.[2]
References
- ↑ Anonymous (2024), ErbB-2 receptor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Hudis CA (2007). "Trastuzumab--mechanism of action and use in clinical practice.". N Engl J Med 357 (1): 39-51. DOI:10.1056/NEJMra043186. PMID 17611206. Research Blogging.